Joberty Gérard, Boesche Markus, Brown Jack A, Eberhard Dirk, Garton Neil S, Humphreys Philip G, Mathieson Toby, Muelbaier Marcel, Ramsden Nigel G, Reader Valérie, Rueger Anne, Sheppard Robert J, Westaway Susan M, Bantscheff Marcus, Lee Kevin, Wilson David M, Prinjha Rab K, Drewes Gerard
Cellzome GmbH, a GlaxoSmithKline company , Meyerhofstrasse 1, Heidelberg, Germany.
Epinova Discovery Performance Unit, Medicines Research Centre, GlaxoSmithKline R&D , Stevenage, United Kingdom.
ACS Chem Biol. 2016 Jul 15;11(7):2002-10. doi: 10.1021/acschembio.6b00080. Epub 2016 May 19.
The 2-oxoglutarate-dependent dioxygenase target class comprises around 60 enzymes including several subfamilies with relevance to human disease, such as the prolyl hydroxylases and the Jumonji-type lysine demethylases. Current drug discovery approaches are largely based on small molecule inhibitors targeting the iron/2-oxoglutarate cofactor binding site. We have devised a chemoproteomics approach based on a combination of unselective active-site ligands tethered to beads, enabling affinity capturing of around 40 different dioxygenase enzymes from human cells. Mass-spectrometry-based quantification of bead-bound enzymes using a free-ligand competition-binding format enabled the comprehensive determination of affinities for the cosubstrate 2-oxoglutarate and for oncometabolites such as 2-hydroxyglutarate. We also profiled a set of representative drug-like inhibitor compounds. The results indicate that intracellular competition by endogenous cofactors and high active site similarity present substantial challenges for drug discovery for this target class.
依赖于2-氧代戊二酸的双加氧酶靶标类别包含约60种酶,包括几个与人类疾病相关的亚家族,如脯氨酰羟化酶和Jumonji型赖氨酸去甲基化酶。当前的药物发现方法主要基于靶向铁/2-氧代戊二酸辅因子结合位点的小分子抑制剂。我们设计了一种化学蛋白质组学方法,该方法基于连接到珠子上的非选择性活性位点配体的组合,能够从人细胞中亲和捕获约40种不同的双加氧酶。使用游离配体竞争结合形式对珠子结合的酶进行基于质谱的定量,能够全面测定对共底物2-氧代戊二酸和对诸如2-羟基戊二酸等肿瘤代谢物的亲和力。我们还分析了一组具有代表性的类药物抑制剂化合物。结果表明,内源性辅因子的细胞内竞争和高活性位点相似性对该靶标类别的药物发现提出了重大挑战。